Citations

Mayo Clinic

Showing 10 of 108599 citations.

GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancer
Robinson, Jessica , Tzou, Katherine S., Parker, Alexander S. , Wu, Kevin J. , Hilton, Tracy, Pisansky, Thomas M. , Peterson, Jennifer , Vallow, Laura A., Buskirk, Steven J., Hilton, Tracy W, Schild, Steven E. , Peterson, Jennifer L., Heckman, Michael G.

The British Journal of Radiology | May 9, 2017 | Volume: 90 | Issue: 1075 | Pages: No page available

10.1259/bjr.20170174 | PMID 28486040 Get It

Objective: High GATA2 expression has been associated with an increased risk of poor clinical outcomes after radical prostatectomy; however, this has not been studied in relation to risk of biochemical recurrence (BCR) after salvage radiation therapy (SRT) for recurrent prostate cancer after radical prostatectomy. Our aim was to evaluate the association between protein expression levels of GATA2 in primary prostate cancer tumour samples and the risk of BCR after SRT. Methods: 109 males who were treated with SRT were included. The percentage of cells with nuclear staining and GATA2 staining intensity were both measured. These two measures were multiplied together to obtain a GATA2 H-score (range 0–12) which was our primary GATA2 staining measure. Results: In unadjusted analysis, the risk of BCR was higher for patients with a GATA2 H-score >4 (hazard ratio = 2.04, p = 0.033). In multivariable analysis adjusting for SRT dose, pre-SRT PSA, pathological tumour stage and Gleason score, this association weakened substantially (hazard ratio = 1.45, p = 0.31). This lack of an independent association with BCR appears to be the result of correlations between GATA2 H-score >4 and higher pre-SRT PSA (p = 0.021), higher Gleason score (p = 0.044) and more severe pathological tumour stage (p = 0.068). Conclusion: Higher levels of GATA2 expression appear to be a marker of prostate cancer severity; however, these do not provide independent prognostic information regarding BCR beyond that of validated clinicopathological risk factors. Advances in knowledge: A higher GATA2 expression level appears to be correlated with known measures of prostate cancer severity and therefore is likely not an independent marker of outcome after SRT.
Designed Ankyrin Repeat Proteins: A Look at their Evolving Use in Medicine with a Focus on the Treatment of Chorioretinal Vascular Disorders
Smithwick, Elizabeth M., Stewart, Michael W.

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry | May 9, 2017 | Volume: 16 | Issue: 1 | Pages: 33-45

10.2174/1871523016666170502115816 | PMID 28464780 Get It

Background: Antibodies constitute an important drug development platform for drugs to treat several ophthalmic, oncologic, and immunologic conditions, but due to limitations inherent in antibody production and structure, a wide range of other protein binding scaffolds are being investigated. Designed ankyrin repeat proteins (DARPins) are simple to produce and offer a range of advantages over antibodies because of their stability, high binding affinity, and rigid structure. Objective: DARPins are being developed for a wide variety of medical applications, and the most studied molecule, abicipar pegol, is used to treat chorioretinal vascular diseases. This mini-review will discuss the current state of DARPin technology and will summarize drug development with a focus on abicipar. Methods: PubMed searches with keywords “DARPin” and “designed ankyrin repeat proteins” were performed and the reference lists of identified articles were examined for additional research material. Studies using DARPin molecules were identified at Clinicaltrials. gov. Non-peer reviewed data were found through Google searches of pertinent websites. Results: Abicipar prevents angiogenesis by binding all isoforms of vascular endothelial growth factor (VEGF)-A with single-digit picomolar affinity. Abicipar has a long intraocular half-life in rabbits and has produced promising results in pre-clinical studies. Pivotal phase III registration trials for the treatment of neovascular age-related macular degeneration are ongoing and a phase II/III trial for the treatment of diabetic macular edema has been announced. Conclusion: Abicipar pegol has the potential to effectively treat chorioretinal vascular conditions with an extended duration of action beyond those of currently used anti-VEGF drugs.
Diagnostic dilemmas in Alzheimer's disease: Room for shared decision making
Flier, Wiesje M. van der , Kunneman, Marleen , Petersen, Ronald C. , Smets, Ellen M.A. , Bouwman, Femke H. , van der Flier, Wiesje M

Alzheimer's & Dementia: Translational Research & Clinical Interventions | May 9, 2017 | Volume: 3 | Issue: 3 | Pages: 301-304

10.1016/j.trci.2017.03.008 | PMID 29067336 Get It

Abstract The launch of the NIA‐AA research criteria for Alzheimer's disease (AD) diagnosis illustrates the large advances that have been made in the field of AD diagnosis. These new possibilities however also introduce new dilemmas into the consulting room, and this provides room for shared decision making (SDM). SDM refers to clinicians and patients (and/or their caregivers) working together to decide which care plan best fits individual patients and their lives, when there is more than one reasonable option. Here, we describe how SDM in the diagnosis of AD promotes patient‐centered care, as it helps to adapt the diagnostic process to the patients' values and preferences. We provide an outline for a research agenda, as SDM in the diagnosis of dementia should be studied intensively incorporating the views of both patients and caregivers.
What to do when you question cardiac troponin values
Mair, Johannes , Huber, Kurt , Möckel, Martin , Thygesen, Kristian , Jaffe, Allan S. , Lindahl, Bertil , Giannitsis, Evangelos , Plebani, Mario , Jaffe, Allan S. , Huber, Kurt , Mockel, Martin

European Heart Journal: Acute Cardiovascular Care | May 9, 2017 | Volume: 7 | Issue: 6 | Pages: 577-586

10.1177/2048872617708973 | PMID 28485179 Get It

High-sensitivity cardiac troponin assays enable cardiac troponin measurement with a high degree of analytical sensitivity and a low level of analytical imprecision at the low measuring range. One of the most important advantages of these new assays is that they allow novel, more rapid approaches for ruling in or ruling out acute myocardial infarctions. The increase in the early diagnostic sensitivity of high-sensitivity cardiac troponin assays comes at the cost of a reduced acute myocardial infarction specificity of the biomarker, because more patients with other causes of acute or chronic myocardial injury without overt myocardial ischaemia are detected than with previous cardiac troponin assays. Increased troponin concentrations that do not fit with the clinical presentation are seen in the daily routine, mainly as a result of a variety of pathologies, and if tested in the same sample, even discrepancies between high-sensitivity cardiac troponin I and troponin T test results may sometimes be found as well. In addition, analytically false-positive test results occasionally may occur since no assay is perfect. In this review, we summarise the biochemical, pathophysiological and analytical background of the work-up for such a clinical setting.
Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms
Botero, Juliana Perez , Ho, Thanh P. , Kenderian, Saad S. , Gangat, Naseema , Tefferi, Ayalew , Abraham, Roshini S. , Nguyen, Phuong L., Oliveira, Jennifer L. , He, Rong , Chen, Dong , Viswanatha, David S., Rodriguez, Vilmarie , Khan, Shakila P. , Patnaik, Mrinal M. , Herrick, Jennifer L. , Perez Botero, Juliana , Viswanatha, David, Hogan, William J. , Kenderian, Saad Sirop , Chen, Dong

British Journal of Haematology | May 9, 2017 | Volume: 182 | Issue: 1 | Pages: 141-145

10.1111/bjh.14746 | PMID 28485484 Get It

The National Living Donor Assistance Center perspective on barriers to the use of federal travel grants for living donors
Mathur, Amit K. , Ojo, Akinolu, Merion, Robert M. , Hong, Barry A.

Clinical Transplantation | May 9, 2017 | Volume: 31 | Issue: 7 | Pages: No page available

10.1111/ctr.12984 | PMID 28485106 Get It

AbstractRecent research has identified important barriers that potential living organ donors face in utilizing travel reimbursement funds from the National Living Donor Assistance Center (NLDAC). In this article, we provide clarification and comment on these potential barriers from the NLDAC program perspective. The goal of financial neutrality for living donors requires further action. We discuss recent developments and further steps that may help achieve this goal and ultimately affect the shortage of donor organs.
Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy
Barreto, Jason N. , McCullough, Kristen , Peskey, Candy S , Dierkhising, Ross , Mara, Kristin C. , Elliott, Michelle A. , Gastineau, Dennis A. , Al‐Kali, Aref , Gangat, Naseema , Letendre, Louis, Litzow, Mark R. , Patnaik, Mrinal M. , McCullough, Kristen B, Dierkhising, Ross A, Hogan, William J , Litzow, Mark R. , Patnaik, Mrinal , Hogan, William J. , McCullough, Kristen B , Mara, Kristin C

Leukemia & Lymphoma | May 9, 2017 | Volume: 58 | Issue: 11 | Pages: 2588-2597

10.1080/10428194.2017.1312384 | PMID 28482728 Get It

Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure
Rafique, Zubaid , Weir, Matthew R. , Lafayette, Richard , Butler, Javed , Farnum, Carolyn, Onuigbo, Macaulay , Pitt, Bertram , Lopes, Maria Carolina Barbosa Teixeira , Peacock, William Frank

Journal of Managed Care & Specialty Pharmacy | May 9, 2017 | Volume: 23 | Issue: 4-a Suppl | Pages: S10-S19

10.18553/jmcp.2017.23.4-a.s10 | PMID 28485203 Get It

Management of macroglobulinaemia
Gertz, Morie A.

British Journal of Haematology | May 9, 2017 | Volume: 177 | Issue: 5 | Pages: 669-671

10.1111/bjh.14742 | PMID 28485069 Get It

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
Kumar, Shaji , Moreau, Philippe , Mateos, María‐Victoria , Shustik, Chaim, Masszi, Tamás , Spencer, Andrew , Hájek, Roman , Romeril, Kenneth, Avivi, Irit , Liberati, Anna Marina , Berg, Deborah, Lin, Jianchang , Gupta, Neeraj , Esseltine, Dixie‐Lee, Richardson, Paul G. , Einsele, Hermann , Gupta, Neeraj , Hari, Parameswaran , Ludwig, Heinz , Minnema, Monique C , Lonial, Sagar , Richardson, Paul Gerard Guy , Hajek, Roman , Moreau, Philippe , Masszi, Tamas

British Journal of Haematology | May 9, 2017 | Volume: 178 | Issue: 4 | Pages: 571-582

10.1111/bjh.14733 | PMID 28485007 Get It

SummaryThe oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was based on the global, randomised, double‐blind, placebo‐controlled Phase III TOURMALINE‐MM1 study of ixazomib‐Rd (IRd) versus placebo‐Rd in patients with relapsed/refractory multiple myeloma. IRd resulted in a significant improvement in progression‐free survival versus placebo‐Rd (median: 20·6 vs. 14·7 months; hazard ratio 0·74). Common toxicities observed more commonly with IRd versus placebo‐Rd were thrombocytopenia, nausea, vomiting, diarrhoea, constipation, rash, peripheral neuropathy, peripheral oedema and back pain; these were generally grade 1/2 in severity except for thrombocytopenia (19% vs. 9% grade 3/4), which appeared manageable and reversible, with no differences between arms in significant bleeding or dose discontinuations. No cumulative toxicities were observed, indicating the potential feasibility of long‐term IRd treatment. Safety data from TOURMALINE‐MM1 are reviewed and guidance for managing clinically relevant adverse events associated with IRd is provided. Most toxicities were manageable with supportive care and dose delays or reductions as needed. Clinicians should be aware of and understand these potential side effects to optimise and prolong patient benefit.